Regeneron Pharmaceuticals Inc. is promoting its early genetics research as the backbone of its R&D organization, providing a powerful advantage over rivals that will deliver a new wave of medicines into the clinic and eventually to market.
Regeneron is talking up its early research at the Regeneron Genetics Center (RGC) at a time when the company's big-seller Eylea (aflibercept) is maturing, new blockbusters have not materialized and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?